A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 7, 2012, Pages 430-437

  Bendell, Johanna C ^a,b   Meluch, Anthony ^c   Peyton, James ^c   Rubin, Mark ^c   Waterhouse, David ^d   Webb, Charles ^e   Burris, Howard A ^c   Hainsworth, John D ^c  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Tennessee Oncology ^*  (United States)

^d Oncology Hematology Care Inc   (United States)

^e SCRI   (United States)

Author keywords

Chemotherapy; Esophageal cancer; Radiation therapy; Targeted therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; FLUOROURACIL; LACTATE DEHYDROGENASE; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ASCITES; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARDIOPULMONARY ARREST; COLITIS; CONTINUOUS INFUSION; DEATH; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; ODYNOPHAGIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PREOPERATIVE TREATMENT; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84864390180     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer. 2008;123:1422-1428.
3. Tepper JE, Krasna M, Niedzwiecki D, et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. Proc Am Soc Clin Oncol. 2006;24:181s.
4. Rohatgi PR, Swisher SG, Correa AM, et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006;106:552-558.
5. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337.
6. Seydel HG, Leichman L, Byhardt R, et al. Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: an RTOG study. Int J Radiat Oncol Biol Phys. 1988;14:33-35.
7. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118-1123.
8. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
9. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic state predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
10. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003;9:251-260.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinote- can, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
12. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;335:2542-2550.
13. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat. 2005;94:792-799.
14. Rades D, Golke H, Schild SE, Kilic E. Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol. 2008;184:416-420.
15. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001;61:39-44.
16. Takaoka M, Harada H, Andl CD, et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 2004;64:7711-7723.
17. Kopp R, Ruge M, Rothbauer E, et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. 2002;22:1161-1167.
18. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9-S15.
19. Chinnaiyan P, Huang S, Vallabhaneni G, et al., Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328-3335.
20. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
21. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659-668.
22. Leichman L, Goldman BH, Benedetti JK, et al. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): a Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27: Abstract 4513.
23. Cagol M, Ruol A, Sileni VC, et al. [Multimodal treatment in locally advanced esophageal cancer: a multicenter phase II study with neoadjuvant oxaliplatin, 5-fluorouracil, leucovorin and neoadjuvant radiotherapy: preliminary results]. Chir Ital. 2006;58:433.
24. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20:2844.
25. Brenner B, Ilson DH, Minsky BD, et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 2004;22:45.
26. Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18:2032.
27. Anne PR, Axelrod R, Rosato E, et al. A phase II trial of preoperative paclitaxel, carboplatin, 5-FU and radiation in patients with resectable esophageal or gastric cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;22: Abstract 4031.
28. Urba S, Hayman J, Ianettonni M, et al. Preoperative chemoradiation with cisplatin (CDDP), 5-fluorouracil (5-FU), and paclitaxel (Tax), followed by surgery and adjuvant chemotherapy, for loco-regional esophageal carcinoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;22: Abstract 31.
29. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003;9:251-260.
30. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201-5206.
31. Jhawer M, Tse A, Ilson D, et al. Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma. Abstract presented at: 2009 Gastrointestinal Cancer Symposium; January 15-17, 2009; San Francisco, CA. Abstract 10.
32. Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26: Abstract 4552.
33. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922-4927.
34. Tew WP, Kelsen DP, Ilson DH. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Oncologist. 2005;10:590-601.
35. Ilson DH, Bains M, Rizk N, et al. Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27: Abstract 4573.
36. Sunpaweravong P, Sunpaweravong S, Sangthawan D, et al. Combination of gefitinib, cisplatin, and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25: Abstract 4605.
37. Juergens RA, Gibson MK, Yang SC, et al. Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemotherapy (CRT) in operable esophageal adenocarcinoma (EAC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28: Abstract e14532.
38. Enzinger P, Yock T, Suh W, et al. Phase II cisplatin, irinotecan, cetuximab, and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24: Abstract 4064.
39. Lordick F, Meyer zum Büschenfelde C, Thuss-Patience P, et al. Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): a phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2009;15s:e15507.
40. Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase Ib-II trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06). J Clin Oncol. 2011;29:626-631.
41. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28:43-48.